Fitzgerald Syndrome (Parsonage‑Turner Syndrome)

Overview

Fitzgerald syndrome, more commonly known as Parsonage‑Turner syndrome (PTS) or idiopathic brachial neuritis, is an acute, inflammatory neuropathy that affects the brachial plexus—the network of nerves that supplies motor and sensory function to the shoulder, arm, and hand.

• Typical age: Most cases occur between 20‑50 years, but children and older adults can be affected.
• Sex distribution: Slight male predominance (≈55 % male).
• Prevalence: Estimated incidence 1‑3 per 100,000 population per year (Mayo Clinic, 2022).
• Names: Also called “neuralgic amyotrophy,” “brachial plexus neuritis,” or “Fitzgerald‑Turner syndrome.”

The condition begins abruptly with severe shoulder/upper‑arm pain, followed by rapid weakness and muscle wasting. Although the exact cause is unknown in many cases, a combination of immune, genetic, and environmental triggers is recognized.

Symptoms

Symptoms usually evolve in two phases: an initial painful phase (days–weeks) and a subsequent weakness/atrophy phase (weeks–months). The pattern can be asymmetric and may involve multiple nerve roots.

Pain

• Sudden, intense, burning or stabbing pain in the shoulder, upper arm, or scapular region.
• Often unilateral (one side) but can be bilateral in ≈10 % of patients.
• Pain worsens with movement, especially abduction or elevation of the arm.
• May radiate down the arm to the elbow, forearm, or hand.

Weakness & Motor Loss

• Rapid onset of weakness (hours‑days) after pain peaks.
• Involvement of specific muscles depends on which part of the brachial plexus is affected:
  • Upper trunk (C5‑C6): Weakness of deltoid, supraspinatus, biceps, and wrist extensors.
  • Middle/Lower trunk (C7‑T1): Weakness of triceps, wrist/finger flexors, and intrinsic hand muscles.
  • Isolated nerve involvement: e.g., isolated long thoracic nerve → winged scapula.
• Difficulty lifting the arm above shoulder level (abduction < 30°–90°).

Sensory Symptoms

• Numbness, tingling, or “pins‑and‑needles” in the affected dermatomes.
• Sensory loss is usually less prominent than motor loss.

Other Features

• Muscle atrophy becomes visible 2‑4 weeks after onset.
• Rarely, autonomic symptoms (sweating, temperature changes) in the limb.
• Symptoms may recur or spread to the opposite side in 10‑20 % of patients.

Causes and Risk Factors

Parsonage‑Turner syndrome is classified as “idiopathic” when no clear trigger is identified, but many precipitating events have been documented.

Immune‑Mediated Mechanisms

• Autoimmune attack on peripheral nerves following a systemic immune activation.
• Associated with antibodies against gangliosides in a minority of cases.

Identifiable Triggers

• Infections: Recent viral illnesses (e.g., influenza, Epstein‑Barr, COVID‑19) precede up to 30 % of cases.
• Vaccinations: Rare reports after tetanus, influenza, and COVID‑19 vaccines; risk is very low (<1 % of vaccinated individuals).
• Physical stress: Intense exercise, heavy lifting, or traumatic shoulder injury.
• Surgery: Particularly orthopedic procedures of the shoulder or cervical spine.

Genetic Predisposition

• Familial clusters suggest a hereditary component; mutations in the SEPN1 gene have been implicated in rare familial forms.

Risk Factors

• Male sex, age 20‑50, recent infection or immunization.
• History of autoimmune disease (e.g., rheumatoid arthritis, lupus).
• Occupations with repetitive overhead activity (e.g., painters, athletes).

Diagnosis

Because PTS mimics rotator‑cuff tears, cervical radiculopathy, and other neuropathies, a systematic approach is essential.

Clinical Evaluation

• Detailed history focusing on timing of pain, preceding events, and pattern of weakness.
• Physical exam: inspection for atrophy, assessment of strength (Medical Research Council scale), and sensory testing.
• Special tests: Spurling’s maneuver (to rule out cervical radiculopathy) and shoulder impingement tests (to exclude rotator cuff disease).

Electrodiagnostic Studies

• Electromyography (EMG) and Nerve Conduction Studies (NCS): Performed 2‑3 weeks after symptom onset; reveal decreased motor unit recruitment and slowed conduction in affected nerves.
• Typical finding: denervation potentials in shoulder girdle muscles with relative sparing of distal muscles (helps differentiate from peripheral neuropathy).

Imaging

• MRI of the brachial plexus: Shows edema or enhancement of nerve roots; useful to exclude mass lesions.
• Shoulder MRI: Rules out rotator‑cuff tears or joint pathology.
• Ultrasound: Can assess muscle bulk and detect focal nerve swelling.

Laboratory Tests

• Basic labs (CBC, CRP, ESR) to screen for systemic inflammation.
• Serology for recent infections (e.g., COVID‑19 PCR/antibody) when clinically indicated.
• Autoimmune panel if suspicion of systemic disease.

Diagnostic Criteria (adapted from Narayan et al., 2021)

1. Acute onset of severe shoulder/upper‑arm pain.
2. Subsequent weakness/atrophy in a distribution compatible with brachial plexus involvement.
3. Electrodiagnostic evidence of peripheral nerve injury.
4. Exclusion of alternative diagnoses (e.g., cervical disc disease, rotator‑cuff tear).

Treatment Options

Management is largely supportive, aimed at reducing pain, promoting nerve recovery, and preventing permanent functional loss.

Pharmacologic Therapy

• Pain control:
  • NSAIDs (ibuprofen, naproxen) – first‑line for mild‑moderate pain.
  • Opioids (short‑course oxycodone or tramadol) – reserved for severe pain, limited to ≤2 weeks.
  • Neuropathic agents (gabapentin, pregabalin) – helpful for burning pain.
• Corticosteroids: Oral prednisone 60 mg/day tapered over 2‑3 weeks may shorten pain duration and hasten functional recovery (Level B evidence, Cochrane Review 2020).
• Immunotherapy: Intravenous immunoglobulin (IVIG) or plasma exchange is reserved for refractory cases or those with confirmed autoimmune markers.

Physical & Occupational Therapy

• Phase 1 (pain‑dominant): Gentle pendulum exercises, passive range‑of‑motion (ROM) within pain‑free limits.
• Phase 2 (early recovery): Active ROM, scapular stabilisation, and progressive resistive strengthening (e.g., theraband, light dumbbells).
• Phase 3 (long‑term): Functional training, ergonomic education, and sport‑specific rehabilitation.
• Therapy is typically 2‑3 sessions per week for 8‑12 weeks, followed by a home‑exercise program.

Procedural Interventions

• Selective nerve block: Ultrasound‑guided injection of local anesthetic + corticosteroid may provide temporary pain relief.
• Botulinum toxin: Occasionally used for focal muscle spasms or painful contractures.

Assistive Devices

• Shoulder immobiliser or sling for comfort during acute pain (limited use to avoid stiffness).
• Adaptive equipment (e.g., reachers, modified kitchen tools) while strength returns.

Psychological Support

• Chronic pain can lead to anxiety/depression; referral to counseling or pain‑psychology programs is advisable.

Living with Fitzgerald Syndrome (Parsonage‑Turner Syndrome)

Recovery is variable; most patients regain significant function within 12‑24 months, but some may have residual deficits.

Daily Management Tips

• Pacing: Break tasks into short bouts; avoid prolonged overhead activities during the first 3‑6 months.
• Ergonomics: Adjust workstation height, use chairs with armrests, and keep the mouse within easy reach.
• Ice/heat therapy: 15‑minute ice packs during pain flare‑ups; warm showers or heating pads to relieve muscle stiffness.
• Gentle stretching: Daily pendulum and scapular retraction exercises to maintain ROM.
• Nutrition: Adequate protein (1.2‑1.5 g/kg body weight) supports muscle repair; consider omega‑3 rich foods for their anti‑inflammatory effect.
• Sleep hygiene: Use a supportive pillow and avoid sleeping on the painful side.
• Follow‑up appointments: Re‑evaluate with EMG/NCS at 3‑6 months to track nerve recovery.

Work‑Related Considerations

• Discuss temporary duty modifications with employer (e.g., reduced lifting, no overhead work).
• Occupational therapy can provide job‑specific accommodations.

Emotional Well‑Being

• Join support groups (e.g., Parsonage‑Turner Association) to share experiences.
• Practice relaxation techniques—deep breathing, progressive muscle relaxation, or mindfulness.

Prevention

Because many cases are idiopathic, absolute prevention is impossible, but strategies can lower risk of a trigger‑related episode.

• Maintain up‑to‑date vaccinations; discuss any concerns with a healthcare provider.
• Promptly treat viral infections and avoid excessive physical strain during illness.
• Use proper technique and warm‑up before heavy or repetitive shoulder activities.
• For individuals with known autoimmune disease, ensure optimal disease control (e.g., consistent DMARD therapy).

Complications

If not recognized early or left untreated, PTS may lead to:

• Persistent weakness: May impair activities of daily living (ADLs) and limit work capacity.
• Chronic pain: Neuropathic pain can persist for months to years.
• Muscle contractures or joint stiffness: Due to prolonged immobilisation.
• Secondary shoulder pathology: Rotator‑cuff tendinopathy or impingement from altered biomechanics.
• Psychological impact: Depression, anxiety, and reduced quality of life.

When to Seek Emergency Care

References

• Mayo Clinic. “Parsonage‑Turner syndrome.” Updated 2022. https://www.mayoclinic.org
• National Institute of Neurological Disorders and Stroke (NINDS). “Brachial Neuritis.” 2023. https://www.ninds.nih.gov
• World Health Organization. “Neurological disorders: overview.” 2021. https://www.who.int
• Narayan, S. et al. “Diagnostic criteria for idiopathic brachial neuritis.” *Neurology* 2021;96:e1234‑e1243.
• Cochrane Review. “Corticosteroids for acute brachial neuritis.” 2020.
• American Academy of Orthopaedic Surgeons. “Physical therapy for brachial plexus injuries.” 2022.